Pfizer Anticipates Tax Savings and Revenue Growth via US$160 B Mega-Merger with Allergan
By Heather Cartwright, Sayani Datta, Rohit Khera & Keshav Mahawar
Pharma Deals Review: Vol 2016 Issue 1 (Table of Contents)
Published: 14 Jan-2016
DOI: 10.3833/pdr.v2016.i1.2138 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
After failing in its bid to acquire AstraZeneca in 2014, Pfizer has found another means of moving its tax domicile from the US by agreeing to merge with Allergan in a US$160 B deal...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS